Advanced Search
AIDS

The Economic Returns to Investment in AIDS Treatment in Low and Middle Income Countries

in

"The Economic Returns to Investment in AIDS Treatment in Low and Middle Income Countries," is one of the first efforts to look systematically at the expected economic benefits (returns) to large scale investment in AIDS treatment.

Despite the remarkable scale-up of AIDS treatment and prevention programs in low and middle income countries in recent years, each year two million people die from AIDS (most without ever having received antiretrovirals ART) and 2.7 million are newly infected by HIV.

Published in the Public Library of Science (PLoS) One, "The Economic Returns to Investment in AIDS Treatment in Low and Middle Income Countries," is one of the first efforts to look systematically at the expected economic benefits (returns) to large scale investment in AIDS treatment.

Publication & Resource Type: 
Journal Articles
R4D Author(s): 
Kira Thorien
R4D Author(s): 
Robert Hecht
R4D Author(s): 
Stephen Resch
Attached Publications & Resources: 
application/pdf iconR4D PLoS ONE Final Manuscript 10.5.11.pdf

PEPFAR, R4D & ICF Macro kickoff new project on AIDS financing

in
24 October, 2011

To strengthen financing frameworks for its country partnerships, PEPFAR has requested assistance from Results for Development Institute and ICF Macro over a 30 month period beginning in October 2011.

Connected Expert(s): 
Gabrielle Partridge
Connected Expert(s): 
Kira Thorien
Connected Expert(s): 
Robert Hecht

AIDS Reaches 30 Year Mark

in
6 June, 2011

On Monday, May 30, a Washington Post article featured findings from the aids2031 Costs and Financing Project, directed by R4D.

On Monday, May 30, the Washington Post featured findings from the aids2031 Costs and Financing Project, directed by R4D, in the article, "Tough decisions about money and treatment are ahead as AIDS turns 30," quoting R4D Managing Director, Robert Hecht.

aids2031 

Connected Expert(s): 
Robert Hecht
Connected Project(s): 
aids2031: Costs and Financing Working Group
Connected Publications & Resources: 
Costs & Choices: Financing the Long-Term Fight Against AIDS

R4D Helps Shape Global Fund Strategy

in
12 May, 2011

At its twenty-third Board meeting in May 2011, the Global Fund to Fight Aids, Tuberculosis and Malaria adopted two high-impact policy measures developed in close conjunction with Results for Development Institute (R4D).

R4D Helps Shape Global Fund Strategy

At its twenty-third Board meeting in May 2011, the Global Fund to Fight Aids, Tuberculosis and Malaria adopted two high-impact policy measures developed in close conjunction with Results for Development Institute (R4D). These included a market dynamics strategy and a package of new eligibility policies.

Connected Project(s): 
Review of The Global Fund's Eligibility Criteria

The Long-Run Costs and Financing of HIV/AIDS in Cambodia

in

How can Cambodia best fight its HIV/AIDS epidemic? This report examines the long-term costs and epidemiological projections of HIV/AIDS in Cambodia.

Cambodia has made exceptional progress in addressing HIV/AIDS since it first appeared in the country in 1991. At the height of the epidemic in the early 1990s, approximately 15,500 people were becoming newly infected annually. Since then, Cambodia has greatly reduced the number of new infections – to about 2,100 in 2009. In addition, 93% percent of those eligible to receive antiretroviral therapy are currently in treatment.

Publication & Resource Type: 
Publications
Year Published: 
2010
Main Contact: 
Gabrielle Partridge
R4D Author(s): 
Richard Skolnik
R4D Author(s): 
Robert Hecht
Attached Publications & Resources: 
application/pdf iconCambodia_FINAL_PDF.pdf

The Long-Run Costs and Financing of HIV/AIDS in Cambodia

in
3 January, 2011

"The Long-Run Costs and Financing of HIV/AIDS in Cambodia" was launched on December 21, 2010 in Phnom Penh, Cambodia. Robert Hecht, Results for Development Institute (R4D) Managing Director,  presented the findings at a meeting with the Cambodian Parliament.  

The Long-Run Costs and Financing of HIV/AIDS in Cambodia was launched on December 21, 2010,  in Phnom Penh, Cambodia.  Robert Hecht, Results for Development Institute (R4D) Managing Director, presented the report findings at a meeting with the Cambodia Parliament.

Connected Expert(s): 
Richard Skolnik
Connected Expert(s): 
Robert Hecht
Connected Project(s): 
aids2031: Costs and Financing Working Group
Attached File(s): 
application/msword iconCambodia-aids2031_press_release_FINALversion.doc
application/pdf iconCambodia_FINAL_PDF.pdf
application/vnd.ms-powerpoint iconDec 21 aids 2031 Cambodia_for parlement Eng.ppt

Long-Run Costs and Financing of HIV/AIDS in South Africa

in

South Africa is facing a mounting financial challenge in its fight against the growing HIV/AIDS epidemic. With 5.7 million people currently infected with the HIV virus and an additional half million adults and children becoming newly infected each year, South Africa stands at a critical crossroads.

South Africa is facing a mounting financial challenge in its fight against the growing HIV/AIDS epidemic. With 5.7 million people currently infected with the HIV virus and an additional half million adults and children becoming newly infected each year, South Africa stands at a critical crossroads.

Publication & Resource Type: 
Publications
Year Published: 
2010
Main Contact: 
Gabrielle Partridge
R4D Author(s): 
Farzana Muhib
R4D Author(s): 
Robert Hecht
Author(s): 
Teresa Guthrie, Nhlanhla Ndlovu, Kelsey Case
Funder(s): 
The Bill and Melinda Gates Foundation
Funder(s): 
The Norwegian Agency for Development Cooperation (NORAD)
Funder(s): 
UNAIDS
Connected Project: 
aids2031: Costs and Financing Working Group
Attached Publications & Resources: 
application/pdf iconaids2031 South Africa Report_Published 2010.pdf

aids2031 South Africa report launches "The Long-Run Costs and Choices of HIV/AIDS in South Africa"

in
22 November, 2010

On November 19th, the aids2031 South Africa report, The Long-Run Costs and Choices of HIV/AIDS in South Africa was launched in Daveyton, South Africa. Read our feature story to learn more.

 

Click here to read the New York Times profile.

Connected Expert(s): 
Robert Hecht
Connected Project(s): 
aids2031: Costs and Financing Working Group
Connected Publications & Resources: 
Costs & Choices: Financing the Long-Term Fight Against AIDS
The Long-Run Costs and Choices of HIV/AIDS in South Africa
Attached File(s): 
application/pdf iconaids2031_South-Africa_Report_FINAL2.pdf

aids 2031: Findings On HIV/AIDS Cost and Financing Strategies in The Lancet

in

In a Review in the Lancet, authors from the financing group of the aids2031 project address critical questions about HIV/AIDS, taking a long-term view of financial requirements under different possible scenarios as the pandemic unfolds over the next two decades up to 2031

What can developing countries do now to change the trajectory of the AIDS epidemic for decades to come? How much will it cost to avert new infections and expand access to treatment? Which countries will be able to take full ownership of their HIV/AIDS responses, and which will continue to rely on international support?

Publication & Resource Type: 
Journal Articles
Year Published: 
2010
Main Contact: 
Robert Hecht
R4D Author(s): 
David de Ferranti
R4D Author(s): 
Farzana Muhib
R4D Author(s): 
Robert Hecht
Connected Project: 
aids2031: Costs and Financing Working Group
Link to Publication-Resource: 
aids2031:costs_and_choices
Attached Publications & Resources: 
application/pdf iconLancet aids2031 Final.pdf

Lancet Publishes aids2031 Findings On HIV/AIDS Cost and Financing Strategies

in
8 October, 2010

What can developing countries do now to change the trajectory of the AIDS epidemic for decades to come? How much will it cost to avert new infections and expand access to treatment? Which countries will be able to take full ownership of their HIV/AIDS responses, and which will continue to rely on international support?

What can developing countries do now to change the trajectory of the AIDS epidemic for decades to come?  How much will it cost to avert new infections and expand access to treatment?  Which countries will be able to take full ownership of their HIV/AIDS responses, and which will continue to rely on international support?

Connected Expert(s): 
Robert Hecht
Connected Project(s): 
aids2031: Costs and Financing Working Group
Connected Publications & Resources: 
Costs & Choices: Financing the Long-Term Fight Against AIDS
Attached File(s): 
application/pdf iconLancet aids2031 Final.pdf
Syndicate content